Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

BIAF vs SHPH: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SHPH Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 8–0 Matrix Metrics)

SHPH Overall Winner 6-Pillar Tally: BIAF 2 – 2 SHPH (2 Tie) Matrix Metrics: BIAF 0 – 8 SHPH

As of Nov 20, 2026, Shuttle Pharmaceuticals Holdings, Inc. (SHPH) is the stronger overall head-to-head candidate over bioAffinity Technologies, Inc. (BIAF) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). BIAF carries a Unified Composite Score of 48.0/100 (HOLD) at $1.65 (N/M Forward P/E, -246.1% operating margin), whereas SHPH carries 48.3/100 (HOLD) at $3.49 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: BIAF is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.3); meanwhile SHPH trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 31.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BIAF vs SHPH
BIAF NASDAQ
bioAffinity Technologies, Inc. Common Stock
Services-Commercial Physical & Biological Research
$1.65
-10.81% 1D
Market Cap $3.3M
TTM Revenue $5.5M
Forward P/E N/M
Beta / 30D Vol -0.62β · 120% Vol
Unified Composite Score
48.0 / 100 HOLD
Tech 38.0 Fund 51.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -22.0%), weak momentum, RSI 31
RSI-14: 31.3 · SMA20: $2.52 · SMA50: $4.51
SHPH NASDAQ Head-to-Head Winner
Shuttle Pharmaceuticals Holdings, Inc. Common Stock
Pharmaceutical Preparations
$3.49
-10.51% 1D
Market Cap $17.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 9.23β · 88% Vol
Unified Composite Score
48.3 / 100 HOLD
Tech 38.0 Fund 47.0 Flow 50.0 Mom 46.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 32
RSI-14: 31.8 · SMA20: $4.83 · SMA50: $4.53

6-Pillar Scorecard Institutional Category Breakdown (BIAF 2 – 2 SHPH)

Columns: Metric · BIAF · SHPH
1. Valuation Multiples BIAF
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 0.4x N/M
2. Growth & Scale SHPH
Revenue Growth (YoY) -26.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $5.5M N/A
Market Cap $3.3M $17.6M
3. Profitability & Quality SHPH
Gross Margin 27.0% N/A
Operating Margin -246.1% 0.0%
Net Profit Margin -278.9% 0.0%
Return on Equity (ROE) -240.5% -90.0%
4. Balance Sheet & Cash Flow BIAF
Cash Generation (TTM) -$13M EBITDA -$12M
Cash Flow Margin N/A N/A
Net Cash / Leverage -$994,714 Net Debt (0.38x D/E) -$875,933 Net Debt (0.06x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Diagnostics & Research Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BIAF (0) vs SHPH (8)
Institutional Metric BIAF SHPH Criterion Row Edge
Market Capitalization
Scale
$3.3M $17.6M Larger Scale SHPH
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-26.0% +0.0% Higher Growth SHPH
Operating Margin (TTM)
Profitability
-246.1% 0.0% Higher Margin SHPH
Net Profit Margin
Profitability
-278.9% 0.0% Higher Margin SHPH
Return on Equity (ROE)
Capital Efficiency
-240.5% -90.0% Higher ROE SHPH
52-Week Range Position
Momentum
7% ($0–$20) 54% ($0–$6) Stronger Trend SHPH
Beta / 30D Volatility
Risk Regime
-0.62β · 120% Vol 9.23β · 88% Vol Lower Realized Risk SHPH
Unified Institutional Score
Composite Signal
48.0 / 100 (HOLD) 48.3 / 100 (HOLD) Higher Composite SHPH
Trailing 12M Revenue (USD)
Operating Scale
$5.5M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
27.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.4x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$13M EBITDA (-$994,714 Net Debt (0.38x D/E)) -$12M (-$875,933 Net Debt (0.06x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SHPH +23.65 pp
BIAF: -47.95% · SHPH: -24.3%
3M Horizon SHPH +70.8 pp
BIAF: -71.65% · SHPH: -0.85%
6M Horizon SHPH +493.58 pp
BIAF: +5.77% · SHPH: +499.35%
1Y Horizon SHPH +64.02 pp
BIAF: +12.24% · SHPH: +76.26%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BIAF vs SHPH. Trailing 12-month operating profitability (BIAF -246.1% vs SHPH 0.0%) and valuation multiples (BIAF N/M vs SHPH N/M Forward P/E) are benchmarked directly in Pillar 4 below.

BIAF ADR TTM Benchmark FX-Normalized USD
TTM Revenue$5.5M
Gross Margin27.0%
Op. Margin-246.1%
ROE / Fwd P/E-240.5% · N/M
SHPH ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-90.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BIAF UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BIAF Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SHPH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SHPH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BIAF Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $3.3M market capitalization and -246.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SHPH Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $17.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BIAF vs SHPH Key Questions & Quantitative Answers

As of Nov 20, 2026, Shuttle Pharmaceuticals Holdings, Inc. (SHPH) is the stronger overall head-to-head candidate over bioAffinity Technologies, Inc. (BIAF) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). BIAF carries a Unified Composite Score of 48.0/100 (HOLD) at $1.65 (N/M Forward P/E, -246.1% operating margin), whereas SHPH carries 48.3/100 (HOLD) at $3.49 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: BIAF is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.3); meanwhile SHPH trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 31.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SHPH leads the Growth & Scale pillar: BIAF posts -26.0% YoY revenue growth and +0.0% YoY earnings growth on $5.5M TTM revenue (27.0% gross margin, -246.1% operating margin), compared with SHPH at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, BIAF generates $5.5M in USD-normalized revenue versus N/A for SHPH. In operating R&D and SG&A reinvestment, BIAF deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SHPH.

BIAF screens cheaper on headline valuation multiples. BIAF trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.4x EV/Revenue (unreported EBITDA margin), whereas SHPH trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BIAF (-240.5% ROE) versus SHPH (-90.0% ROE) capital efficiency.

In options market volatility and institutional positioning, BIAF carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.62β · 120% Vol realized risk). By comparison, SHPH carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (9.23β · 88% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.